GRTX
Galera Therapeutics, Inc. OTC$0.10
Mkt Cap $7.4M
52w Low $0.01
61.6% of range
52w High $0.15
50d MA $0.06
200d MA $0.03
P/E (TTM)
0.1x
EV/EBITDA
0.7x
P/B
1.4x
Debt/Equity
0.0x
ROE
3750.6%
P/FCF
-0.4x
RSI (14)
—
ATR (14)
—
Beta
1.77
50d MA
$0.06
200d MA
$0.03
Avg Volume
296.8K
About
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe or…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.30 | 0.66 | +320.0% | 0.05 | -4.0% | -8.9% | -9.1% | -13.1% | -5.1% | -8.1% | +91.3% | — |
| Nov 13, 2025 | AMC | — | -0.01 | — | 0.02 | -0.8% | +3.4% | -5.1% | -2.1% | +1.3% | -15.6% | +1.3% | — |
| Aug 13, 2025 | AMC | — | -0.01 | — | 0.02 | +1.8% | -2.7% | -0.4% | +6.6% | -2.2% | -0.4% | -4.9% | — |
| May 15, 2025 | AMC | — | -0.01 | — | 0.02 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -4.2% | +20.8% | — |
| Mar 31, 2025 | AMC | -0.30 | -0.08 | +73.3% | 0.03 | +0.0% | +0.0% | -6.7% | -6.7% | -16.7% | -10.0% | -26.7% | — |
| Dec 13, 2024 | AMC | -0.29 | -0.06 | +79.3% | 0.03 | -10.0% | -5.0% | -13.0% | -10.0% | -8.3% | +3.3% | +57.0% | — |
| Aug 14, 2024 | AMC | 0.83 | -0.07 | -108.5% | 0.07 | +2.8% | +8.5% | +8.5% | +7.0% | -9.3% | -7.3% | -4.2% | — |
| May 13, 2024 | AMC | -0.29 | -0.08 | +72.8% | 0.18 | -5.7% | -0.5% | +8.0% | +11.0% | +11.4% | +5.9% | -43.8% | — |
| Mar 28, 2024 | AMC | -0.29 | -0.10 | +65.0% | 0.14 | +38.5% | +18.7% | +7.9% | +10.1% | +15.7% | +18.6% | +30.4% | — |
| Nov 14, 2023 | AMC | -0.44 | -0.33 | +25.0% | 0.14 | -4.6% | +3.4% | +3.3% | -0.3% | -2.4% | -6.4% | -2.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 29 | Citigroup | Maintains | Neutral → Neutral | — | $0.21 | $0.21 | +1.5% | +1.5% | +2.4% | +1.9% | +2.9% | +4.4% |
| Aug 16 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.27 | $0.26 | -3.7% | -7.0% | -14.1% | -18.1% | -16.7% | -20.4% |
| Aug 10 | Piper Sandler | Downgrade | Overweight → Neutral | — | $2.24 | $0.39 | -82.8% | -83.9% | -85.6% | -86.6% | -87.9% | -88.8% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.78 | +1.1% | +8.0% | +4.4% | +5.1% | +2.2% | -0.4% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.08 | -2.3% | -5.6% | +0.0% | +3.3% | +15.5% | +22.5% |
| Feb 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.72 | $1.79 | +4.1% | +9.3% | +12.8% | +9.3% | +2.9% | +3.5% |
| Feb 16 | BofA Securities | Upgrade | Underperform → Buy | — | $1.66 | $1.82 | +9.6% | -4.2% | +3.6% | +13.3% | +16.9% | +13.3% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.66 | $1.82 | +9.6% | -4.2% | +3.6% | +13.3% | +16.9% | +13.3% |
| May 27 | BofA Securities | Downgrade | Neutral → Underperform | — | $1.74 | $1.64 | -5.7% | -6.9% | -8.0% | -14.9% | -8.0% | -4.0% |
| Dec 20 | Citigroup | Maintains | Buy → Buy | — | $2.96 | $3.49 | +17.9% | +28.0% | +49.0% | +41.9% | +59.5% | +70.6% |
Recent Filings
S-4
!!! Very High
Gazelle Parent, Inc. -- Merger Registration
Gazelle Parent's merger registration shows the combined entity will have only $1.8 million in cash, indicating tight liquidity that could constrain operations post-closing.
Apr 22
8-K
Unknown — 8-K Filing
GRTX shareholders' options will convert to parent company stock in a merger, diluting existing equity and potentially reducing per-share value depending on conversion terms and parent's share count.
Apr 14
8-K
Unknown — 8-K Filing
This 8-K appears to be a routine procedural filing with minimal substantive disclosures, suggesting no material corporate events occurred that would directly impact GRTX's valuation or operations.
Apr 9
8-K
Unknown — 8-K Filing
Gritstone bio faces a potential proxy contest with a shareholder deadline of April 13, 2026, suggesting activist involvement that could disrupt management or board composition if investor dissatisfaction exists.
Apr 3
8-K
Galera Therapeutics, Inc. -- 8-K Filing
This 8-K filing appears to be a procedural submission without material business updates, providing no clear investment implications for Galera Therapeutics shareholders at this time.
Feb 18
8-K
Galera Therapeutics, Inc. -- 8-K Filing
Galera Therapeutics filed an 8-K reporting material corporate developments, though specific details remain unclear from the available summary information.
Feb 12
Data updated apr 28, 2026 10:17am
· Source: massive.com